Robot surgery may spare seminoma patients from chemo side effects

NCT ID NCT06144736

Recruiting now Disease control Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase II trial is testing whether robot-assisted surgery to remove lymph nodes in the abdomen can help predict and prevent cancer recurrence in men with stage II seminoma. About 60 participants will undergo the procedure, with the option of one round of chemotherapy afterward. The goal is to reduce long-term side effects from standard treatments while keeping survival rates high.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Robot-assisted retroperitoneal lymph node dissection (surgery) and optional one cycle of cisplatin, etoposide, and bleomycin (chemotherapy)
What this could lead to: If successful, this approach could allow some men with seminoma to avoid long-term side effects of chemotherapy while maintaining high survival rates.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Surgery carries risks like infection or nerve damage, and cancer may still return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEMINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

seminoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEMINOMA

Contacts and locations

Locations

University Hospital of Duesseldorf
RECRUITING

Düsseldorf, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.